or Try an Advanced Search...

    Technical Analysis for RCE - Recce Ltd  

    Grade Last Price % Change Price Change
    A 0.530 0.00% 0.000
    RCE closed unchanged on Friday, April 19, 2024, on 3.82 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical RCE trend table...
    Date Alert Name Type % Chg
    200 DMA Support Bullish 0.00%
    Volume Surge Other 0.00%
    Outside Day Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Down Weakness 0.00%
    NR7 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Inside Day Range Contraction 0.00%
    Older End-of-Day Signals for RCE ...

       Recent Intraday Alerts

    Alert Time
    200 DMA Resistance 1 day ago
    Gap Down Closed 1 day ago
    Reversed from Down 1 day ago
    10 DMA Support 1 day ago
    200 DMA Support 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    RCE Chart by TradingView
    Basic chart:

    Profile

    Recce Ltd   Description

    Recce Limited is an Australia-based research-based pharmaceutical company. The Company is principally engaged in research and development of antibiotic drugs and anticancer drugs. The Company's antibiotics kill both susceptible bacteria and drug resistant super bugs throughout the world health danger arising from resistance to present-day antibiotics. The Company offers antibiotic drugs to treat the diseases caused by Sepsis, Helicobacter Pylori (H.Pylori), Escherichia coli (E.coli), Gonorrhea and Tuberculosis (TB). The Company offers anticancer drugs to treat various cancers, such as leukemia, prostate, lung, stomach, intestine, kidney and melanoma. The Company also offers polymer-antibiotics targeted for human use. The Company's Recce antibiotic kills all types of bacteria, including superbugs. Its subsidiaries include Recce (USA) LLP and Recce (UK) Limited.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Major
    Keywords: Health Medicine Pharmaceutical Disease Cancer Diseases Drugs Cancers Resistance Pharmaceuticals Policy Bacteria Bacteriology Antibiotic Chemotherapy Antibiotics Leukemia Melanoma Stomach Veterinary Medicine

    Is RCE a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 17 Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
    Apr 10 Recce Pharmaceuticals Provides Business Update
    Apr 10 Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
    Apr 4 Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
    Mar 22 Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
    Mar 19 Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
    Mar 14 Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
    Mar 13 Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
    Mar 12 Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
    Feb 29 Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
    See more RCE news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 0.785
    52 Week Low 0.41
    Average Volume 169,449
    200-Day Moving Average 0.519
    50-Day Moving Average 0.465
    20-Day Moving Average 0.473
    10-Day Moving Average 0.500
    Average True Range 0.025
    RSI (14) 63.64
    ADX 33.81
    +DI 30.097
    -DI 15.762
    Chandelier Exit (Long, 3 ATRs) 0.490
    Chandelier Exit (Short, 3 ATRs) 0.505
    Upper Bollinger Bands 0.546
    Lower Bollinger Band 0.400
    Percent B (%b) 0.89
    BandWidth 30.740
    MACD Line 0.021
    MACD Signal Line 0.011
    MACD Histogram 0.0094
    Fundamentals Value
    Market Cap 92.02 Million
    Num Shares 174 Million
    EPS -0.03
    Price-to-Earnings (P/E) Ratio -17.67
    Price-to-Sales 0.00
    Price-to-Book 81.46
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.605
    Resistance 3 (R3) 0.602 0.573 0.593
    Resistance 2 (R2) 0.573 0.554 0.575 0.588
    Resistance 1 (R1) 0.552 0.542 0.563 0.555 0.584
    Pivot Point 0.523 0.523 0.529 0.525 0.523
    Support 1 (S1) 0.502 0.504 0.513 0.505 0.476
    Support 2 (S2) 0.473 0.492 0.475 0.472
    Support 3 (S3) 0.452 0.473 0.468
    Support 4 (S4) 0.455